التجارب السريرية بالأسفل التجارب السريرية الحالية.562 دراسات في علم الأورام (طبي) (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that is metastatic (spread to other parts of the body), has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR), has a certain type of abnormal gene called "BRAF," and has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take encorafenib by mouth at home every day and cetuximab by IV infusion at the study clinic. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic. E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the overall rate of response of brain metastases in subjects with central nervous system (CNS) metastases due to metastatic melanoma with a BRAF V600 mutation who have relapsed or progressed from initial or systemic disease. . A Study to Evaluate Combination Therapy to Treat Newly-diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Rochester, Minn. The purpose of this study is to evaluate how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT). A Study to Evaluate Individualized Prehabilitation for People Undergoing Neo-Adjuvant Radiotherapy and Lower Limb Soft-Tissue Sarcoma Surgery Scottsdale/Phoenix, Ariz. The primary objectives of this study are to determine if a tailored prehabilitation program focusing on functional optimization of spared limb tissue in two groups of patients with localized, lower extremity soft tissue sarcoma, one with prehabilitation and one with equal attention and informational support, improves functional outcome as measure by the Toronto Extremity Salvage Score (TESS), to identify the measures and metrics most responsive to the intervention using the (TESS), Six Minute Walk Test (6MWT)[5], wearable Heel2Toe sensor technology and daily step count, and to estimate recruitment, retention, adherence, and acceptability rates. Colorectal Cancer Screening in Black and Underserved Communities in the Phoenix Metro Area Scottsdale/Phoenix, Ariz. The aims of this study are to increase the number of Black consultants at MCA, make a meaningful impact on interactions among staff, leadership, and patients, and increase the number of Black staff in leadership roles beyond Diversity and Inclusion efforts. Response Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to estimate the rate of sustained MRD negativity (MRD negative status at any point, with a repeated MRD negative status one year later) in subjects with high-risk multiple myeloma. A Study of AP160-Complex in Advanced Solid Tumors Rochester, Minn. This is a single arm phase I study designed to determine the MTD and toxicity profile of the AP160 complex (nab-paclitaxel/STI-3031 complex) in the treatment of advanced or metastatic non-neurological solid tumors using the standard cohort 3+3 design (5 dose levels) followed by an expansion cohort of an additional 6 patients. Patients are dosed Days 1, 8, and 15 of every 28 day cycle. Response will be assessed per RECIST 1.1; patients will have CT/MRI ~Q8WK (2 cycles) on study. Patients will have tumor biopsies at screening and EOT to evaluate PDL1 expression and TME. Blood samples will be taken for PK and immune response studies. STI-3031, a fully human anti-PDL1 recombinant monoclonal Ab, will be supplied by Sorrento. Abraxane will be obtained commercially and the complex will be made at Mayo prior to each administration. Needle-based Confocal Laser Endomicroscopy Guided For Lung Cancer Diagnosis: A Randomized Controlled Trial Rochester, Minn., Jacksonville, Fla. The purpose of this study is to compare per pass diagnostic yield of different numbers of sequential needle passes (ROSE) and the procedure duration needed to obtain a contributive TBNA sample with ROBOTIC-guided TBNA to that of ROBOTIC-guided nCLE in PPNs. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) Rochester, Minn. The purpose of the study is to evaluate the effectiveness, safety and patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study Jacksonville, Fla. The purpose of this study ia to determine the safety and tolerability of personalized neoantigen peptide administered in combination with pembrolizumab to patients with advanced solid tumors. Patients' tumors will be sequenced during a pre-registration component or will have had successful sequencing pre-study. A personalized neoantigen peptide vaccine containing up to 20 unique peptides will be manufactured for each qualifying patient based on the results. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 2424 توجّه للصفحة 2525 توجّه للصفحة 2626 توجّه للصفحة 2727 توجّه للصفحة 2828 التاليالصفحة التالية طلب تحديد موعد الخبرة و مراتب التصنيفبحث 09/05/2023 صنَّفت شبكة U.S. News & World Report مستشفيات مايو كلينك في مدينة روتشستر بولاية مينيسوتا وفي مدينة جاكسونفيل بولاية فلوريدا وفي مدينتيّ فينيكس/سكوتسديل بولاية أريزونا ضمن أفضل مستشفيات علاج السرطان في الولايات المتحدة لعام 2023-2024. اعرف المزيد عن هذا الشرف الرفيع علم الأورام (طبي)القسمالرئيسيالأقساممُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20180179 الأقسام والمراكز الطبية علم الأورام (طبي)